Get the Stockscreener App
20.96
3.14%
-0.68
Apellis Pharmaceuticals Inc stock is traded at $20.96, with a volume of 1.87M.
It is down -3.14% in the last 24 hours and down -3.90% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
See More
Previous Close:
$21.64
Open:
$21.3
24h Volume:
1.87M
Relative Volume:
0.68
Market Cap:
$2.68B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-10.33
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-5.92%
1M Performance:
-3.90%
6M Performance:
-25.73%
1Y Performance:
-19.38%
1-Day Range:
$20.79
$21.30
1-Week Range:
$20.10
$22.77
52-Week Range:
$16.10
$30.48
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
20.96 | 2.77B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Jan-21-26 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis (APLS) Q4 2025 Earnings Call Transcript - AOL.com
Analysts Issue Forecasts for APLS FY2030 Earnings - MarketBeat
Apellis price target lowered to $18 from $20 at Wedbush - Yahoo Finance
Apellis Pharmaceuticals Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
RBC Capital Adjusts Price Target for Apellis Pharmaceuticals (AP - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $44.00 by Analysts at Citigroup - MarketBeat
APLS: Citigroup Maintains Rating, Lowers Price Target to $44.00 - GuruFocus
Mizuho Securities Adjusts Apellis Pharmaceuticals PT to $20 From $19, Maintains Neutral Rating - marketscreener.com
Royal Bank Of Canada Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $21.00 - MarketBeat
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Nasdaq
Why Apellis Pharmaceuticals Stock Is Under Pressure - TipRanks
RBC Capital Adjusts Apellis Pharmaceuticals PT to $21 From $22, Maintains Sector Perform Rating - marketscreener.com
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $18.00 at Wedbush - MarketBeat
APLS: Analyst Wedbush Lowers Price Target to $18 While Maintaini - GuruFocus
H.C. Wainwright raises Apellis stock price target on Syfovre outlook - Investing.com Australia
HC Wainwright & Co. Raises Price Target for APLS to $48.00 | APLS Stock News - GuruFocus
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 51% Upside Potential - DirectorsTalk Interviews
Apellis Pharmaceuticals (APLS) Profitability Shift Tests Bullish Narratives After Q4 Loss - simplywall.st
Apellis Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Apellis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Wedbush Adjusts Apellis Pharmaceuticals Price Target to $18 From $20, Maintains Neutral Rating - marketscreener.com
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates - Bitget
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Apellis Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Apellis Pharmaceuticals Q4 2025 reveals strong product demand - Investing.com
Apellis (APLS) Surpasses Revenue Expectations in Q4 - GuruFocus
APELLIS PHARMACEUTICALS ($APLS) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss - marketscreener.com
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Apellis Pharmaceuticals Earnings Report: Q4 Overview - Benzinga
Apellis Pharmaceuticals, Inc. SEC 10-K Report - TradingView
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Pairs Strong Growth with Bullish Chart Setup - ChartMill
A Glimpse of Apellis Pharmaceuticals's Earnings Potential - Benzinga
Apellis earnings on deck: Can new kidney drug revive growth momentum? By Investing.com - Investing.com Canada
Apellis earnings on deck: Can new kidney drug revive growth momentum? - Investing.com Nigeria
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
(APLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - MSN
RTW INVESTMENTS, LP Acquires Significant Stake in Apellis Pharma - GuruFocus
Apellis announces eight oral presentations at the 49th Macula Society annual meeting - marketscreener.com
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting - Bitget
5-year SYFOVRE study tackles eye disease that leads to blindness for millions - Stock Titan
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Readystate Asset Management LP Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline - Finviz
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday - MarketBeat
BofA upgrades Apellis (APLS) to buy citing rapid Empaveli adoption and underappreciated kidney disease market potential - MSN
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):